HomeCompareGNFTF vs VICI

GNFTF vs VICI: Dividend Comparison 2026

GNFTF yields 19.18% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $919.4K in total portfolio value· pulled ahead in Year 5
10 years
GNFTF
GNFTF
● Live price
19.18%
Share price
$10.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$6,165.13
Full GNFTF calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — GNFTF vs VICI

📍 VICI pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFTF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFTF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFTF
Annual income on $10K today (after 15% tax)
$1,629.91/yr
After 10yr DRIP, annual income (after tax)
$5,240.36/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $524,531.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFTF + VICI for your $10,000?

GNFTF: 50%VICI: 50%
100% VICI50/50100% GNFTF
Portfolio after 10yr
$529.1K
Annual income
$314,713.23/yr
Blended yield
59.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

GNFTF
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
0.2
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFTF buys
0
VICI buys
0
No recent congressional trades found for GNFTF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTFVICI
Forward yield19.18%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$69.4K$988.8K
Annual income after 10y$6,165.13$623,261.32
Total dividends collected$38.6K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: GNFTF vs VICI ($10,000, DRIP)

YearGNFTF PortfolioGNFTF Income/yrVICI PortfolioVICI Income/yrGap
1$12,618$1,917.55$11,368$948.43+$1.3KGNFTF
2$15,762$2,261.19$13,339$1,493.16+$2.4KGNFTF
3$19,505$2,639.91$16,326$2,426.21+$3.2KGNFTF
4$23,924$3,053.13$21,123$4,112.15+$2.8KGNFTF
5← crossover$29,098$3,499.76$29,379$7,368.23$281.00VICI
6$35,113$3,978.25$44,804$14,191.64$9.7KVICI
7$42,058$4,486.56$76,658$29,972.12$34.6KVICI
8$50,024$5,022.33$150,894$71,015.81$100.9KVICI
9$59,109$5,582.83$350,814$193,582.47$291.7KVICI
10$69,411$6,165.13$988,809$623,261.32$919.4KVICI

GNFTF vs VICI: Complete Analysis 2026

GNFTFStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFTF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this GNFTF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFTF vs SCHDGNFTF vs JEPIGNFTF vs OGNFTF vs KOGNFTF vs MAINGNFTF vs NNNGNFTF vs EPRTGNFTF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.